Thomas Horvatits
Dr. med. univ. Dr. scient. med.
Thomas Horvatits
  • Oberarzt
  • Facharzt für Innere Medizin
  • Facharzt für Innere Medizin und Gastroenterologie
Arbeitsbereich

Kontakt

Standort

Hauptgebäude O10 , 2. Etage
Sprachen
Deutsch (Muttersprache)
Englisch

Fachgebiete

Tätigkeitsschwerpunkte

Publikationen

Zurück
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
Vor

Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial
Wehmeyer M, Horvatits T, Buchholz A, Krause L, Walter S, Zapf A, Lohse A, Kluwe J
TRIALS. 2022;23(1):302.

Hepatitis E, Schistosomiasis and Echinococcosis-Prevalence in a Cohort of Pregnant Migrants in Germany and Their Influence on Fetal Growth Restriction
Zöllkau J, Ankert J, Pletz M, Mishra S, Seliger G, Lobmaier S, Prazeres Da Costa C, Seidel V, Weizsäcker K, Jablonka A, Dopfer C, Baier M, Horvatits T, Reiter-Owona I, Groten T, Schleenvoigt B
PATHOGENS. 2022;11(1):.

HEV-Associated Neuralgic Amyotrophy : A Multicentric Case Series
Bannasch J, Berger B, Schwartkopp C, Berning M, Goetze O, Panning M, Fritz-Weltin M, Trendelenburg G, Gelderblom M, Lütgehetmann M, Stute F, Horvatits T, Dirks M, Antoni C, Behrendt P, Pischke S
PATHOGENS. 2021;10(6):.

Lower Levels of Transaminases but Higher Levels of Serum Creatinine in Patients with Acute Hepatitis E in Comparison to Patients with Hepatitis A
Brehm T, Mazaheri O, Horvatits T, Lütgehetmann M, Schulze Zur Wiesch J, Lohse A, Polywka S, Pischke S
PATHOGENS. 2021;10(1):60.

Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis
Buescher G, Ozga A, Lorenz E, Pischke S, May J, Addo M, Horvatits T
LIVER INT. 2021;41(3):449-455.

Risk factors associated with bleeding after prophylactic endoscopic variceal ligation in cirrhosis
Drolz A, Schramm C, Seiz O, Groth S, Vettorazzi E, Horvatits T, Wehmeyer M, Schramm C, Goeser T, Roesch T, Lohse A, Kluwe J
ENDOSCOPY. 2021;53(3):226-234.

Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity
Drolz A, Wolter S, Wehmeyer M, Piecha F, Horvatits T, Schulze Zur Wiesch J, Lohse A, Mann O, Kluwe J
INT J OBESITY. 2021;45(10):2197-2204.

Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic
Fründt T, Kuballa L, Lütgehetman M, Nörz D, Arend H, Brehm T, Schulze Zur Wiesch J, Horvatits T, Horvatits K, Huber S, Wege H, Kluwe J
PLOS ONE. 2021;16(12):e0258450.

Hepatitis E: vom akut-auf-chronischen Leberversagen bis zur chronischen Hepatitis E
Horvatits T
Der Gastroenterologe. 2021;2021:.

Improvement of renal function prior to liver transplantation is not associated with better long-term renal outcome or survival
Horvatits T, Hübener P, Touma M, Horvatits K, Fischer L, Lohse A, Sterneck M
ANN HEPATOL. 2021;26:.

Hepatitis E virus persists in the ejaculate of chronically infected men
Horvatits T, Wißmann J, Johne R, Groschup M, Gadicherla A, Wiesch J, Eiden M, Todt D, Reimer R, Dähnert L, Schöbel A, Horvatits K, Lübke R, Wolschke C, Ayuk F, Rybczynski M, Lohse A, Addo M, Herker E, Lütgehetmann M, Steinmann E, Pischke S
J HEPATOL. 2021;75(1):55-63.

Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era
Piecha F, Gänßler J, Ozga A, Wehmeyer M, Kluwe J, Lampalzer S, Creutzfeldt A, Buescher G, Horvatits T, Sterneck M, Pischke S, Lohse A, Schulze Zur Wiesch J
SCAND J GASTROENTERO. 2021;56(7):840-848.

Lack of Evidence for an Association between Previous HEV Genotype-3 Exposure and Glomerulonephritis in General
Pischke S, Tamanaei S, Mader M, Wiesch J, Petersen-Benz C, Haddad M, Addo M, Schmidt T, Huber T, Krebs C, Steinmetz O, Turner J, Hoxha E, Horvatits T
PATHOGENS. 2021;11(1):.

Significance of Anti-Nuclear Antibodies and Cryoglobulins in Patients with Acute and Chronic HEV Infection
Horvatits T, Schulze Zur Wiesch J, Polywka S, Buescher G, Lütgehetmann M, Hussey E, Horvatits K, Peine S, Haag F, Addo M, Lohse A, Weiler-Normann C, Pischke S
PATHOGENS. 2020;9(9):.

No link between male infertility and HEV genotype 3 infection
Horvatits T, Varwig-Janssen D, Schulze Zur Wiesch J, Lübke R, Reucher S, Frerk S, Addo M, Schneider S, Lohse A, Luetgehetmann M, Pischke S
GUT. 2020;69(6):1150-1151.

Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study
Kamar N, Abravanel F, Behrendt P, Hofmann J, Pageaux G, Barbet C, Moal V, Couzi L, Horvatits T, De Man R, Cassuto E, Elsharkawy A, Riezebos-Brilman A, Scemla A, Hillaire S, Donnelly M, Radenne S, Sayegh J, Garrouste C, Dumortier J, Glowaki F, Matignon M, Coilly A, Figueres L, Mousson C, Minello A, Dharancy S, Rerolle J, Lebray P, Etienne I, Perrin P, Choi M, Marion O, Izopet J
CLIN INFECT DIS. 2020;71(5):1204-1211.

Monocytes as potential mediators of pathogen-induced Th17 differentiation in patients with primary sclerosing cholangitis (PSC)
Kunzmann L, Schoknecht T, Poch T, Henze L, Stein S, Kriz M, Grewe I, Preti M, Hartl J, Pannicke N, Peiseler M, Sebode M, Zenouzi R, Horvatits T, Böttcher M, Petersen B, Weiler-Normann C, Hess L, Ahrenstorf A, Lunemann S, Martrus G, Fischer L, Li J, Carambia A, Kluwe J, Huber S, Lohse A, Franke A, Herkel J, Schramm C, Schwinge D
HEPATOLOGY. 2020;72(4):1310-1326.

Lactate Improves Prediction of Short-Term Mortality in Critically Ill Patients With Cirrhosis
Drolz A, Horvatits T, Rutter K, Landahl F, Roedl K, Meersseman P, Wilmer A, Kluwe J, Lohse A, Kluge S, Trauner M, Fuhrmann V
HEPATOLOGY. 2019;69(1):258-269.

Liver injury and failure in critical illness
Horvatits T, Drolz A, Trauner M, Fuhrmann V
HEPATOLOGY. 2019;70(6):2204-2215.

Einsatz von Protonenpumpenhemmern bei Patienten mit Leberzirrhose – eine Umfrage unter Hepatologen in Deutschland
Horvatits T, Drolz A, Wehmeyer M, Steib C, Trebicka J, Lohse A, Kluwe J
Z GASTROENTEROL. 2019;57(6):729-733.

HEV in pregnancy: Understanding the crucial role of steroid hormones
Horvatits T, Pischke S
LIVER INT. 2019;39(4):621-622.

The Clinical Perspective on Hepatitis E
Horvatits T, Schulze Zur Wiesch J, Lütgehetmann M, Lohse A, Pischke S
VIRUSES-BASEL. 2019;11(7):.

Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival
Piecha F, Radunski U, Ozga A, Steins D, Drolz A, Horvatits T, Spink C, Ittrich H, Benten D, Lohse A, Sinning C, Kluwe J
JHEP Reports. 2019;1(2):90-98.

Hypoxic liver injury after in- and out-of-hospital cardiac Arrest: Risk factors and neurological outcome.
Roedl K, Spiel A, Nürnberger A, Horvatits T, Drolz A, Hubner P, Warenits A, Sterz F, Herkner H, Fuhrmann V
RESUSCITATION. 2019;137:175-182.

Akutes Leberversagen: Zeitgerechte Diagnose und Therapie ist entscheidend für die Prognose
Rutter K, Horvatits T, Drolz A, Roedl K, Siedler S, Kluge S, Fuhrmann V
Wiener klinisches Magazin : Beilage zur Wiener klinischen Wochenschrift. 2019;22(1):38-47.

Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis
Wittner M, Schlicker V, Libera J, Bockmann J, Horvatits T, Seiz O, Kummer S, Manthey C, Hüfner A, Kantowski M, Rösch T, Degen O, Huber S, Eberhard J, Schulze Zur Wiesch J
PLOS ONE. 2019;14(7):e0220008.

Acid-base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease
Drolz A, Horvatits T, Roedl K, Rutter K, Brunner R, Zauner C, Schellongowski P, Heinz G, Funk G, Trauner M, Schneeweiss B, Fuhrmann V
ANN INTENSIVE CARE. 2018;8(1):48.

Response for letter "Be cautious in comparing the seroprevalence of hepatitis E detected at different years in different countries"
Horvatits T, Ozga A, Lohse A, Dalton H, Pischke S
LIVER INT. 2018;38(12):2341.

Hepatitis E seroprevalence in the Americas: A systematic review and meta-analysis
Horvatits T, Ozga A, Westhölter D, Hartl J, Manthey C, Lütgehetmann M, Rauch G, Kriston L, Lohse A, Bendall R, Wedemeyer H, Dalton H, Pischke S
LIVER INT. 2018;38(11):1951-1964.

Extrahepatic manifestations and HEV, the genotype matters
Horvatits T, Pischke S
EBIOMEDICINE. 2018;36:3-4.

Outcome and natural course of renal dysfunction in liver transplant recipients with severely impaired kidney function prior to transplantation
Horvatits T, Pischke S, Proske V, Fischer L, Scheidat S, Thaiss F, Fuhrmann V, Lohse A, Nashan B, Sterneck M
UNITED EUR GASTROENT. 2018;6(1):104-111.

Serum-Gallensäuren beim Intensivpatienten: Ursache oder Indikator einer schlechten Prognose?
Horvatits T, Trauner M, Fuhrmann V
Intensiv News. 2018;22(6):13-15.

Lack of evidence for human serum albumin as major source of HEV infections
Horvatits T, Westhölter D, Peine S, Schulze Zur Wiesch J, Lohse A, Lütgehetmann M, Pischke S
TRANSFUSION MED. 2018;28(6):470-471.

Course of HEV viremia and anti-HEV IgM/IgG response in asymptomatic blood donors
Kraef C, Schlein C, Hiller J, Westhölter D, Denzer U, Horvatits T, Peine S, Lohse A, Lütgehetmann M, Polywka S, Pischke S
J CLIN VIROL. 2018;105:26-30.

Persistierender Aszites nach TIPS-Implantation ist prädiktiv für ein geringeres transplantationsfreies Überleben bei Patienten mit Leberzirrhose
Piecha F, Steins D, Drolz A, Wehmeyer M, Horvatits T, Spink C, Ittrich H, Lohse A, Kluwe J
2018. Abstractband GASL 2018. 2018. Aufl. Thieme Deutschlnad, .

Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice
Raevens S, Geerts A, Paridaens A, Lefere S, Verhelst X, Hoorens A, Van Dorpe J, Maes T, Bracke K, Casteleyn C, Jonckx B, Horvatits T, Fuhrmann V, Van Vlierberghe H, Van Steenkiste C, Devisscher L, Colle I
HEPATOLOGY. 2018;68(2):634-651.

Akutes Leberversagen
Rutter K, Horvatits T, Drolz A, Roedl K, Siedler S, Kluge S, Fuhrmann V
MED KLIN-INTENSIVMED. 2018;113(3):174-183.

HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients
Westhölter D, Hiller J, Denzer U, Polywka S, Ayuk F, Rybczynski M, Horvatits T, Gundlach S, Blöcker J, Schulze Zur Wiesch J, Fischer N, Addo M, Peine S, Göke B, Lohse A, Lütgehetmann M, Pischke S
J HEPATOL. 2018;69(1):36-42.

Serum bile acids as marker for acute decompensation and ACLF in patients with non-cholestatic cirrhosis
Horvatits T, Drolz A, Roedl K, Rutter K, Ferlitsch A, Fauler G, Trauner M, Fuhrmann V
LIVER INT. 2017;37(2):224-231.

Serum bile acids in patients with hepatopulmonary syndrome
Horvatits T, Drolz A, Rutter K, Roedl K, Fauler G, Müller C, Kluge S, Trauner M, Schenk P, Fuhrmann V
Z GASTROENTEROL. 2017;55(4):361-367.

Circulating bile acids predict outcome in critically ill patients
Horvatits T, Drolz A, Rutter K, Roedl K, Langouche L, Van den Berghe G, Fauler G, Meyer B, Hülsmann M, Heinz G, Trauner M, Fuhrmann V
ANN INTENSIVE CARE. 2017;7:48.

Outcome of in- and out-of-hospital cardiac arrest survivors with liver cirrhosis
Roedl K, Wallmüller C, Drolz A, Horvatits T, Rutter K, Spiel A, Ortbauer J, Stratil P, Hubner P, Weiser C, Motaabbed J, Jarczak D, Herkner H, Sterz F, Fuhrmann V
ANN INTENSIVE CARE. 2017;7(1):103.

Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications
Staufer K, Roedl K, Kivaranovic D, Drolz A, Horvatits T, Rasoul-Rockenschaub S, Zauner C, Trauner M, Fuhrmann V
LIVER INT. 2017;37(6):843-850.

Outcome and features of acute kidney injury complicating hypoxic hepatitis at the medical intensive care unit
Drolz A, Horvatits T, Roedl K, Rutter K, Staufer K, Haider D, Zauner C, Heinz G, Schellongowski P, Kluge S, Trauner M, Fuhrmann V
ANN INTENSIVE CARE. 2016;6(1):61.

Coagulation parameters and major bleeding in critically ill patients with cirrhosis
Drolz A, Horvatits T, Roedl K, Rutter K, Staufer K, Kneidinger N, Holzinger U, Zauner C, Schellongowski P, Heinz G, Perkmann T, Kluge S, Trauner M, Fuhrmann V
HEPATOLOGY. 2016;64(2):556-68.

Postpylorische Ernährung beim kritisch Kranken - wann und wie?
Drolz A, Horvatits T, Rutter K, Roedl K, Fuhrmann V
2016. DIVI Jahrbuch 2015/2016. Kluge S, Markewitz A, Jorch G, Putensen C, Quintel M, Sybrecht G (Hrsg.). 1. Aufl. Berlin: 313-318.

Extrakorporale Therapien bei Lebererkrankungen
Fuhrmann V, Drolz A, Rutter K, Roedl K, Wüstenberg R, Horvatits T
2016. DIVI Jahrbuch 2015/2016. Kluge S, Markewitz A, Jorch G, Putensen C, Quintel M, Sybrecht G (Hrsg.). 1. Aufl. Berlin: 181-187.

Gut Ding braucht Weile: Plasmaaustausch verbessert das Überleben bei akutem Leberversagen!
Fuhrmann V, Roedl K, Rutter K, Drolz A, Horvatits T, Kluge S, Siedler S
Intensiv News. 2016;20(2):8-10.

von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy
Horvatits (Rutter) K, Etschmaier A, Ferlitsch M, Maieron A, Hametner S, Horvatits T, Paternostro R, Salzl P, Reiberger T, Peck-Radosavljevic M, Quehenberger P, Hofer H, Trauner M, Ferenci P, Ferlitsch A
DIGEST LIVER DIS. 2016;48(10):1194-9.

Hepatokardiale Wechselwirkungen: Interaktionen zweier Organsysteme
Horvatits T, Drolz A, Rutter K, Roedl K, Kluge S, Fuhrmann V
MED KLIN-INTENSIVMED. 2016;111(5):447-452.

Prediction of major bleeding in cirrhotic ICU patients using the dic score and coagulation parameters
Drolz A, Horvatits T, Roedl K, Rutter K, Kneidinger N, Bopp C, Wüstenberg R, Zauner C, Heinz G, Schellongowski P, Perkmann T, Trauner M, Fuhrmann V
INTENS CARE MED. 2015;3(Suppl 1):A972.

Schockleber beim kritisch Kranken: Gibt es nur symptomatische Therapieoptionen?
Fuhrmann V, Horvatits T, Roedl K, Rutter K, Kluge S, Drolz A
Intensiv News. 2015;19(1):15-17.

Prognostic impact of ICG-PDR in patients with hypoxic hepatitis at the intensive care unit
Horvatits T, Kneidinger N, Drolz A, Roedl K, Rutter K, Kluge S, Fuhrmann V
INTENS CARE MED. 2015;3(Suppl 1):A974.

Prognostic impact of ICG-PDR in patients with hypoxic hepatitis
Horvatits T, Kneidinger N, Drolz A, Roedl K, Rutter K, Kluge S, Trauner M, Fuhrmann V
ANN INTENSIVE CARE. 2015;5(1):47.

Statin therapy is associated with reduced incidence of hypoxic hepatitis in critically ill patients
Drolz A, Horvatits T, Michl B, Roedl K, Schellongowski P, Holzinger U, Zauner C, Heinz G, Madl C, Trauner M, Fuhrmann V
J HEPATOL. 2014;60(6):1187-93.

Schockleber und Cholestase beim kritisch Kranken
Drolz A, Horvatits T, Roedl K, Fuhrmann V
MED KLIN-INTENSIVMED. 2014;109(4):228-34.

Gender-specific differences in energy metabolism during the initial phase of critical illness
Drolz A, Wewalka M, Horvatits T, Fuhrmann V, Schneeweiss B, Trauner M, Zauner C
EUR J CLIN NUTR. 2014;68(6):707-11.

HPS: Diagnosis, clinical features, and medical therapy
Fuhrmann V, Drolz A, Rutter K, Horvatits T
Clin Liver Dis (Hoboken). 2014;4(2):46-49.

Extrakorporale Therapien bei Patienten mit Lebererkrankungen auf der Intensivstation
Fuhrmann V, Horvatits T, Drolz A, Rutter K
MED KLIN-INTENSIVMED. 2014;109(4):246-51.

Pulmonale Komplikationen bei Lebererkrankungen
Horvatits T, Drolz A, Kluge S, Fuhrmann V
MED KLIN-INTENSIVMED. 2014;109(4):235-9.

vWF, a screening tool for detection of hepatopulmonary syndrome in patients with liver cirrhosis
Horvatits T, Drolz A, Roedl K, Herkner H, Ferlitsch A, Perkmann T, Müller C, Trauner M, Schenk P, Fuhrmann V
J HEPATOL. 2014;61(3):544-549.

Therapeutic options in pulmonary hepatic vascular diseases
Horvatits T, Fuhrmann V
Exp Rev Clin Pharmacol. 2014;7(1):31-42.

Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients
Horvatits T, Kitzberger R, Drolz A, Zauner C, Jäger W, Böhmdorfer M, Kraff S, Fritsch A, Thalhammer F, Fuhrmann V, Schenk P
ANTIMICROB AGENTS CH. 2014;58(1):94-101.

Role of angiogenic factors/cell adhesion markers in serum of cirrhotic patients with hepatopulmonary syndrome
Raevens S, Coulon S, Van Steenkiste C, Colman R, Verhelst X, Van Vlierberghe H, Geerts A, Perkmann T, Horvatits T, Fuhrmann V, Colle I
LIVER INT. 2014.

Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats
Schwabl P, Payer B, Grahovac J, Klein S, Horvatits T, Mitterhauser M, Stift J, Boucher Y, Trebicka J, Trauner M, Angermayr B, Fuhrmann V, Reiberger T, Peck-Radosavljevic M
J HEPATOL. 2014;60(6):1135-42.

Clinical impact of arterial ammonia levels in ICU patients with different liver diseases
Drolz A, Jäger B, Wewalka M, Saxa R, Horvatits T, Roedl K, Perkmann T, Zauner C, Kramer L, Ferenci P, Fuhrmann V
INTENS CARE MED. 2013;39(7):1227-37.

Hypoxic liver injury and cholestasis in critically ill patients
Horvatits T, Trauner M, Fuhrmann V
CURR OPIN CRIT CARE. 2013;19(2):128-32.

Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling
Reiberger T, Payer B, Schwabl P, Hayden H, Horvatits T, Jäger B, Hummel T, Mitterhauser M, Trauner M, Fuhrmann V, Angermayr B, Peck-Radosavljevic M
LIVER INT. 2013;33(4):561-8.

Letzte Aktualisierung aus dem FIS: 24.06.2022 - 00:38 Uhr